Drugs / HS-20118
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07033234 | May 2025 → Mar 2026 overdue | psoriasis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06846710 | May 2025 → Oct 2026 expected | psoriasis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-15 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results SID 2026 | HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS hspharm.com ↗
HS-20118 has shown promising efficacy signals in the evaluated participants with moderate to severe plaque psoriasis, and a favorable safety profile in both healthy volunteers from China and New Zealand and participants with moderate to severe psoriasis from China. |
| 2026-05-15 | Hansoh BioMedical R&D Company | Results SID 2026 | 翰森制药HS-20118在健康成人及银屑病患者中的I期临床数据发布 hansoh.cn ↗
HS-20118在中重度斑块状银屑病患者中展现出积极的疗效信号，且在中国与新西兰健康志愿者及中国患者群体中均表现出良好的安全性特征. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-15 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | SID 2026 | HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS hspharm.com ↗ |
| 2026-05-15 | Hansoh BioMedical R&D Company | SID 2026 | 翰森制药HS-20118在健康成人及银屑病患者中的I期临床数据发布 hansoh.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06846710 ↗ |
| Route | Oral | “HS-20118 orally” NCT06846710 ↗ |